Clinical trials: STAT3
Ovarian Cancer, Ovarian Neoplasms
AZD9150, a STAT3 Antisense Oligonucleotide, in People With Malignant Ascites
Background: Some people with gastrointestinal or ovarian cancer also have ascites. That is free fluid built up in the abdomen. Researchers want to see if a new drug can affect some of the immune cells in the ascites.
- Conditions
- Ovarian Cancer, Ovarian Neoplasms, Ascites, Gastrointestinal Cancer
- Trial name
- NCT02417753
- Testing
- AZD9150
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- National Cancer Institute (NCI)
Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia
Pyrimethamine for the Treatment of Relapsed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
In this research study we will start by looking for the highest dose of pyrimethamine that can be given safely to CLL patients without severe or unmanageable side effects.
- Trial name
- NCT01066663
- Testing
- pyrimethamine
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- Dana-Farber Cancer Institute
Type 1 Diabetes
Modulation of STAT3 Signaling With Siltuximab in Type 1 Diabetes
The purpose of this study is to evaluate the effects of siltuximab on immune cell functions in patients with Type 1 diabetes (T1D).
- Trial name
- NCT02641522
- Testing
- Siltuximab
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Carla Greenbaum, MD
Breast Cancer
Phase 1b/2 Study of TTI-101 in Combination for Patients With Metastatic Hormone Receptor-Positive and HER2-Negative Breast Cancer
The primary objective of Phase 1b will be to evaluate the safety and tolerability of TTI-101 when added to palbociclib and AI or fulvestrant administered orally to participants with hormone receptor-positive (HR+) human epidermal…
- Trial name
- NCT05384119
- Testing
- TTI-101, Palbociclib, Aromatase inhibitor (AI)
- Where
- 6 sites in United States
- Volunteers
- 6 people
- Sponsor
- Tvardi Therapeutics, Incorporated
Candidiasis, Chronic Mucocutaneous
CAMB/MAT2203 in Patients With Mucocutaneous Candidiasis
This is an open-label, dose-titration trial to study the efficacy, safety, and pharmacokinetics of oral cochleate amphotericin B (CAMB) in the treatment of mucocutaneous candidiasis infections in patients who are refractory or…
- Trial name
- CAMB (NCT02629419)
- Testing
- Amphotericin B
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Matinas BioPharma Nanotechnologies, Inc.
Autosomal-dominant Hyper-IgE Syndrome
Safety, Tolerability, and Immunogenicity of One Dose of NDV 3A Vaccine in People With STAT3-Mutated Hyper-IgE Syndrome
Background: AD-HIES is a disease that weakens the immune system. It puts people at risk for infections, particularly Staph and Candida infections.
- Trial name
- NCT02996448
- Testing
- NDV-3A
- Where
- United States
- Volunteers
- 3 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Advanced Adult Hepatocellular Carcinoma, Hepatocellular Carcinoma Metastatic
A Phase I/Ib Study of AZD9150 (ISIS-STAT3Rx) in Patients With Advanced/Metastatic Hepatocellular Carcinoma
This is a phase I/Ib open-label, multicentre study to assess the safety, tolerability, pharmacokinetics and preliminary anti-tumour activity of AZD9150 in patients with advanced/metastatic hepatocellular carcinoma.
- Trial name
- NCT01839604
- Testing
- AZD9150
- Where
- 7 sites in Hong Kong, Japan and 2 more
- Volunteers
- 58 people
- Sponsor
- AstraZeneca